Polar Capital Holdings Plc Raises Stake in Insulet Corporation $PODD

Polar Capital Holdings Plc raised its holdings in Insulet Corporation (NASDAQ:PODD) by 150.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 148,299 shares of the medical instruments supplier’s stock after purchasing an additional 88,982 shares during the quarter. Polar Capital Holdings Plc owned about 0.21% of Insulet worth $42,153,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PODD. Larson Financial Group LLC increased its position in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in Insulet during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in Insulet during the 4th quarter worth approximately $28,000. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its stake in shares of Insulet by 68.8% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 55 shares during the last quarter. Finally, Fideuram Asset Management Ireland dac purchased a new position in shares of Insulet in the 4th quarter valued at approximately $41,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PODD shares. Bank of America cut their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Raymond James Financial set a $216.00 price objective on shares of Insulet in a research report on Monday, June 8th. Stifel Nicolaus reduced their target price on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Finally, UBS Group set a $219.00 target price on shares of Insulet in a report on Thursday, June 11th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $240.78.

Insulet Trading Down 0.3%

Shares of PODD stock opened at $147.69 on Wednesday. The business’s fifty day moving average price is $167.67 and its 200 day moving average price is $229.40. The firm has a market capitalization of $10.23 billion, a PE ratio of 34.35, a P/E/G ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the company earned $1.02 earnings per share. Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.36% of the stock is owned by company insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.